BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260921T140000
DTEND;TZID=Europe/London:20260921T150000
DTSTAMP:20260907T080214
CREATED:20260821T162109Z
LAST-MODIFIED:20260821T162132Z
UID:10002359-1789999200-1790002800@www.dementiaresearcher.nihr.ac.uk
SUMMARY:World Alzheimer Report 2026 launch
DESCRIPTION:Every advance in dementia diagnosis and treatment begins with research. \nCurrently there are 158 drugs in 192 trials in the pipeline\, however\, to make these new treatments possible\, we need thousands of people living with dementia\, ranging from early\, mid and late stages of the condition\, to take part in clinical trials globally. \nIn light of this critical pivot point in Alzheimer’s disease and dementia treatments and diagnostics\, ADI’s forthcoming 2026 World Alzheimer Report is focusing on clinical trials\, the driving force and sole pathway for these emerging breakthroughs to reach people living with dementia\, as well as inform future breakthroughs. \nJoin us for our upcoming World Alzheimer Report launch webinar\, where leading experts and report contributors will explore the nuances dementia clinical trials\, what participation means for a person living with dementia and what these trials could mean for the future of diagnosis\, treatment and care. \nAs research continues to evolve\, involving people during the early stages of dementia is increasingly important. An early diagnosis can help people access emerging treatment options\, take part in clinical research where appropriate\, and receive the information and support they need sooner. \nWhether you’re a healthcare professional\, researcher\, advocate\, policymaker or someone living with dementia or a carer\, we invite you to be part of this important conversation. \nRegister today and join us as we explore the future of dementia diagnosis and treatment. \nPanellists include:\n\nPaul Gallagher\nJulie Moore\nDr Emer MacSweeney\nProf Zul Merarli\n\nWe are pleased to offer AI translation for this webinar in over 60 languages including: Arabic\, Dutch\, French\, German\, Greek\, Hindi\, Indonesian (Bahasa)\, Italian\, Japanese\, Korean\, Malay\, Polish\, Portuguese\, Spanish\, Swahili\, Swedish\, Tamil\, Thai\, Turkish\, Ukrainian\, Urdu\, and Vietnamese. \nThe webinar will be available for viewing on ADI’s YouTube channel after the event. \n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/world-alzheimer-report-2026-launch/
CATEGORIES:Summit
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2020/05/ADI-e1606238565168.png
LOCATION:https://alzint-org.zoom.us/webinar/register/2917845473773/WN_Z8-LBu-HRLOf5K9PfZB1Jg#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260922
DTEND;VALUE=DATE:20260925
DTSTAMP:20260907T080214
CREATED:20260310T184949Z
LAST-MODIFIED:20260817T154000Z
UID:10002146-1790035200-1790294399@www.dementiaresearcher.nihr.ac.uk
SUMMARY:European Meeting on Imaging in Neurodegeneration
DESCRIPTION:EU-MIND (European Meeting on Imaging in Neurodegeneration) is a European scientific conference dedicated to neuroimaging in neurodegenerative diseases. Initiated by the collective vision of Gaël Chételat\, Julie Gonneaud\, and Robin de Flores from the Inserm Neuropresage Lab (Caen\, France)\, and co-founded by the Fondation Alzheimer\, EU-MIND was born from the need to build a more connected\, visible\, and well-defined European research community in this specialized field. \nThe first edition took place in Caen\, France\, in September 2024\, and was a great success\, bringing together researchers\, clinicians\, and early-career scientists from across Europe. Driven by values of collaboration\, diversity\, and scientific excellence\, EU-MIND is now held every two years in a different European city. \nJoin us in shaping the future of neuroimaging research in neurodegenerative diseases! \nRegister\n\nWhy such a congress?\n\nUnprecedented focus: EU-MIND is dedicated exclusively to neuroimaging in neurodegenerative diseases\, bringing together the European community working on this vital subject.\nNetworking and collaboration: Get in touch with top-level researchers\, clinicians and experts in a dynamic\, interdisciplinary environment.\nScientific excellence: EU-MIND aims to be at the forefront of research in the field of neuroimaging and neurodegenerative diseases\, including Alzheimer’s disease.\nAdvancing research: by bringing together leading experts in the field to discuss and collaborate on current topics and issues\, EU-MIND hope to provide the ideal breeding ground for major advances in the understanding\, prevention and treatment of neurodegenerative diseases.\nSupporting and promoting young researchers in/from Europe\n\nInitiated by the Neuropresage team of the Inserm Caen U1237 unit and organized by the EU-MIND Scientific Committee\, the first edition of EU-MIND is supported by the Fondation Alzheimer. \nOrigins of the congress\nThe inception of EU-MIND was ignited by the collective vision of Gael Chetelat\, Julie Gonneaud\, and Robin de Flores from the Neuropresage team (Caen\, France). Recognizing a conspicuous void within the European neuroimaging community\, they discerned the absence of a dedicated platform for experts in neurodegenerative diseases. Motivated by this observation\, they felt a compelling need to bridge this gap and establish an exclusive forum where researchers\, clinicians\, and engineers across Europe could convene\, exchange insights\, and foster collaborations. EU-MIND emerged organically as the response to this imperative\, paving the way towards a more interconnected and impactful European research landscape in neuroimaging of neurodegenerative diseases. \nWhat is the role of the Fondation Alzheimer ?\nThe Fondation Alzheimer is a private funding organization dedicated to supporting Alzheimer’s research\, innovation\, and prevention efforts at the national\, European\, and international levels. One of its primary objectives is to address gaps in high-priority research areas. \nGiven that neuroimaging in neurodegenerative diseases offers significant advancements in understanding pathophysiology\, diagnosing\, and treating Alzheimer’s disease\, the Fondation Alzheimer plays a pivotal role in shaping in the EU-MIND initiative. \nThe foundation actively contributes its expertise by participating in strategic vision and serving on the Scientific Committee. Moreover\, it provides substantial financial support to cover conference expenses\, travel grants\, and other necessities. \nThe Fondation Alzheimer takes pride in being an early founder of EU-MIND\, ensuring its sustainability\, attractiveness\, and excellence. \n\nABSTRACT SUBMISSION AND TRAVEL AWARDS\n\nWe are inviting abstract submissions for symposium and/or poster presentations at EU-MIND 2026\, focusing on neuroimaging of Alzheimer’s disease and related dementias. \nWe seek original\, ongoing works and preliminary results. New findings are preferred\, but we also welcome updates to prior works or those presented elsewhere before EU-MIND. Abstracts should not be published as a journal article prior to the conference. \nIf you submit an abstract\, you can apply for a travel award (see below). \nWhen submitting your abstract\, please consider: \nSymposium\nTo be eligible for an oral presentation (~15 min) in a symposium\, your work must be within the following topics: \n\nThe role of sleep in neurodegenerative disorders\n Artificial intelligence and machine learning\nTherapeutic interventions and neuroimaging\nImaging Methods\nNon-Alzheimer’s disease /polypathology\nOmics & connectomics\n\nThe selection will be based on the abstract review scores. \nPoster\nThe selection will be based on the abstract review scores. In addition\, you have the option to be considered for the poster award competition. Poster rating will occur during the conference poster sessions. \nYou may also opt to be considered for a Datablitz presentation (a ~3 min oral “teaser” to highlight your poster). Selection will be based on abstract review scores. Please note that there are no topic restrictions for Datablitz presentations\, and be advised that as we have limited space so not all submissions may be accepted. \nYou will be asked whether you’d liked to be considered for any (or all) of these (travel awards\, datablitz\, oral presentation and poster award competition) directly in the abstract submission form. \nAttendance\nThe presenting author should attend in-person for poster\, datablitz and symposia presentations. \nDeadline: March 20th \n\nSubmit an Abstract
URL:https://www.dementiaresearcher.nihr.ac.uk/event/european-meeting-on-imaging-in-neurodegeneration/
LOCATION:University of Barcelona\, Carrer de Casanova 143\, Barcelona\, 08036 Barcelona\, Spain
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/03/EU-MIND-2026.png
GEO:41.3896672;2.1524826
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=University of Barcelona Carrer de Casanova 143 Barcelona 08036 Barcelona Spain;X-APPLE-RADIUS=500;X-TITLE=Carrer de Casanova 143:geo:2.1524826,41.3896672
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260922
DTEND;VALUE=DATE:20260925
DTSTAMP:20260907T080214
CREATED:20260714T113336Z
LAST-MODIFIED:20260821T161010Z
UID:10002318-1790035200-1790294399@www.dementiaresearcher.nihr.ac.uk
SUMMARY:2026: Biomarker Strategies for FTD Clinical Trials
DESCRIPTION:AFTD is dedicated to improving the lives of families coping with FTD and to advancing research into effective treatments and a cure. The FTD Research Roundtable provides a precompetitive space for biopharmaceutical companies to partner and advance drug development for FTD\, with input from regulators and scientific leaders\, all of whom share a common interest in eliminating barriers to success in FTD clinical trials. If you are working on FTD drug development or a related field and you think that you should participate in the Roundtable\, please get in touch with research@theaftd.org. \nThere has been immense growth in companies focusing on FTD drug development. However\, all companies face similar challenges in FTD drug development. AFTD and scientific leaders are seeking to provide a space in which industry can have precompetitive discussions on FTD clinical trial barriers\, seeking solutions\, proposing best practices and ultimately enable FTD drug development in the past several years. As a result\, the FTD Research Roundtable was developed. \nEach program is selected and designed based upon the priorities of the Steering Committee\, with insight from regulators\, scientific leaders\, and advocates. \n2026: Biomarker Strategies for FTD Clinical Trials\n\nDate: September 22-24\, 2026 \nAgenda: Coming soon \nLeadership Committee: \n\nHoward “Howie” Rosen\, MD\, Academic Co-Chair\nGary Romano\, MD\, PhD\, Industry Co-Chair\nCarmela Tartaglia\, MD\, FRCPC\, Academic Chair-Elect\nRichard Tsai\, MD\, MBA\, Industry Chair-Elect\nMichelle Campbell\, PhD\, US Food & Drug Administration\, Division of Neuroscience\nSteffen Thirstrup\, MD\, PhD\, European Medicines Agency\nGlenn Harris\, PhD\, Rainwater Charitable Foundation\nPenny Dacks\, PhD\, AFTD\nJulia Pierrat\, FTD Family Advocate\n\nSteering Committee Members \n\n\nAcelot\nAFTD\nAlexion\nAviadoBio\nBluefield Project to Cure FTD\nCoya Therapeutics\nCritical Path Institute\nDenali Therapeutics\nEuropean Medicines Agency\nOrchard Therapeutics\nOtsuka\nPassage Bio\nRainwater Charitable Foundation\nUS Food & Drug Administration\nVectorY Therapeutics\n\n\nWebsite – https://www.theaftd.org/for-researchers/ftsg/
URL:https://www.dementiaresearcher.nihr.ac.uk/event/2026-biomarker-strategies-for-ftd-clinical-trials/
LOCATION:In-person and Online\, Harvard University\, Boston Campus\, 25 Shattuck St\, Boston\, MA 02115\, United States
CATEGORIES:Workshop
ATTACH;FMTTYPE=image/jpeg:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2022/01/AFTD-e1641552368858.jpg
GEO:42.336902;-71.1034769
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=In-person and Online Harvard University Boston Campus 25 Shattuck St Boston MA 02115 United States;X-APPLE-RADIUS=500;X-TITLE=Harvard University\, Boston Campus\, 25 Shattuck St:geo:-71.1034769,42.336902
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260923T120000
DTEND;TZID=Europe/London:20260923T124500
DTSTAMP:20260907T080214
CREATED:20260731T141725Z
LAST-MODIFIED:20260731T141725Z
UID:10002339-1790164800-1790167500@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Research Showcase - Evaluating Financial Capacity in Neurocognitive Disorders
DESCRIPTION:How do clinicians determine whether someone can still manage their finances. And can biomarkers help improve the assessment of financial decision making in people with neurocognitive disorders. \nThis livestream is part of the Dementia Researcher weekly Showcase series. Each week we host a 45 minute online session bringing researchers together to share their work\, methods\, and ideas. \nIn this session\, Dr Vaitsa Giannouli will explore the clinical evaluation of financial capacity in older people living with neurocognitive disorders. Her research examines how clinicians assess financial decision making\, the challenges involved in distinguishing cognitive decline from financial vulnerability\, and the emerging role biomarkers may play in supporting these assessments. \nThe session will discuss current approaches to evaluating financial capacity\, consider how advances in dementia biomarkers could complement clinical judgement\, and reflect on the ethical and practical implications for healthcare professionals\, patients\, and families. \nDr Vaitsa Giannouli is a psychologist in the Department of Psychology at Democritus University of Thrace\, Greece. Her research focuses on financial capacity\, decision making\, neuropsychological assessment\, and cognitive disorders in older adults. \nAttendees can expect a research focused session with time for questions and discussion. \n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/research-showcase-evaluating-financial-capacity-in-neurocognitive-disorders/
LOCATION:Dementia Researcher Communities App
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/07/Evaluating-Financial-Capacity-in-Neurocognitive-Disorders-Web.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260923T140000
DTEND;TZID=Europe/London:20260923T150000
DTSTAMP:20260907T080214
CREATED:20260825T130133Z
LAST-MODIFIED:20260825T130133Z
UID:10002361-1790172000-1790175600@www.dementiaresearcher.nihr.ac.uk
SUMMARY:AI in Biology Seminar with Professor Caroline Uhler
DESCRIPTION:A new AI for Biological Discovery Seminar Series\, presented by the Francis Crick Institute. \n\n\n\n\nThe Crick AI for Biological Discovery Seminar Series is a new online seminar series established by Professor Mihaela van der Schaar\, Chief AI Scientist at the Francis Crick Institute\, together with Dr Fabian Fröhlich. \nThe series will explore how advances in AI can transform fundamental biological discovery\, helping researchers ask and address new biological questions. It will bring leading speakers working at the interface of AI\, machine learning and biology to the Crick community\, with a focus on AI for fundamental biological discovery. \nThe seminars are intended to stimulate discussion across the Crick about how AI methods can support biological research\, reveal new insights from complex datasets\, and open up new directions for discovery. \nThe talks are open to scientists from other institutes and universities from across London and beyond. You should have a minimum of graduate-level biological knowledge to attend and fully engage with these talks. \nThe talks are open to scientists from other institutes and universities from across London and beyond. You should have a minimum of graduate-level science and technology knowledge to attend and fully engage with these talks. \n\nFor more information on the event\, visit the event website.
URL:https://www.dementiaresearcher.nihr.ac.uk/event/ai-in-biology-seminar-with-professor-caroline-uhler/
LOCATION:Online
CATEGORIES:Seminar
ATTACH;FMTTYPE=image/jpeg:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2018/08/Crick-Institute-logo-e1616787082230.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260924
DTEND;VALUE=DATE:20260926
DTSTAMP:20260907T080214
CREATED:20260313T202917Z
LAST-MODIFIED:20260312T203627Z
UID:10002150-1790208000-1790380799@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Latinos\, Aging & Dementia Symposium
DESCRIPTION:Date: September 24-25\, 2026 – Location: Boston University\, Charles River Campus. Boston\, MA and Online \nAbout the Symposium: \nThe symposium is designed to strengthen research collaborations\, expand scientific capacity\, enhance community engagement\, and advance our shared commitment to health equity in aging and dementia. The event will also offer early-career investigators valuable opportunities to learn about current advances\, connect with peers and mentors\, and engage with a vibrant multidisciplinary community focused on improving dementia care for Latino populations. \nContent and Format: \nThe symposium will address a broad range of topics relevant to ADRD in Latino populations\, including cultural and linguistic influences on cognition\, novel approaches to caregiving and caregiver support\, ongoing clinical trials\, recruitment and retention of Latino participants\, and advances in biomarkers\, genomics\, and access to emerging therapies. \nTopic areas will include: \nBiomarkers and genomics | cognition and assessment | recruitment\, retention and clinical trials | ADRD care and psychosocial interventions | Drug development and therapeutics | Public health and population approaches | The implementation of AI in clinical practice and research \nInvited Speakers: \n\n\nDavid Aguillon MD PhD\, Universidad de Antioquia\, Colombia\nHugo Aparicio MD\, Boston University School of Medicine\nMiguel Arce Renteria PhD\, Columbia University\nSteven Arnold MD\, Massachusetts General Hospital\, Harvard Medical School\nMalaz Boustani MD MPH\, Indiana University School of Medicine\nTim Chang\, MD PhD\, UCLA California Alzheimer’s disease Center\nFelipe Jain MD\, Massachusetts General Hospital\, Harvard Medical School\nMaría Eugenia Martín PhD\, FLENI\, Argentina\nLuis Medina PhD\, University of Houston\nDoris Molina-Henry PhD\, University of Southern California (USC)\nMarcia Pescador Jimenez PhD\, Boston University\nMaria Quiñones-Cordero PhD\, University of Rochester School of Nursing\nDavid Salmon PhD\, University of California\, San Diego\n\n\nProgram Committee Members: \n\n\nYakeel T. Quiroz PhD (Chair)\nMirella Diaz-Santos PhD\nAveri Giudicessi\, MS\nJorge Llibre-Guerra MD\nJaime Perales-Puchalt PhD\nLiliana Ramirez Gomez MD\nMiriam Rodriguez PhD\nMonica Rosselli\, PhD\nSharon Sanz Simon PhD\nDaniel G. Saldana\, PhD \nIdaly Velez Uribe\, PhD \n\n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/latinos-aging-dementia-symposium/
LOCATION:Boston University\, Charles River Campus\, Boston\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2026/03/Latinos-Aging-Dementia-Symposium.png
GEO:42.3555076;-71.0565364
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Boston University Charles River Campus Boston United States;X-APPLE-RADIUS=500;X-TITLE=Charles River Campus:geo:-71.0565364,42.3555076
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260925T123000
DTEND;TZID=Europe/London:20260925T170000
DTSTAMP:20260907T080214
CREATED:20260727T214702Z
LAST-MODIFIED:20260727T214702Z
UID:10002335-1790339400-1790355600@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Dementia Research & Brain Health
DESCRIPTION:Join the Thames Valley Alzheimer’s Research UK Network for an inspiring afternoon exploring the latest advances in dementia research and what they could mean for all of us. \n\n\n\n\nProgramme Highlights: \n\nKeynote speech from Hilary Evans-Newton\, CBE\, CEO of Alzheimer’s Research UK\nHear from leading Oxford experts on the latest dementia research progress\nLearn how to get involved in dementia research\nMingle with people with lived experience and scientific researchers over a cream tea\nPanel discussion: From Discovery to Delivery: Can our health system keep pace? Chaired by Tom Whipple\, Science editor for The Times\n\n\nRegister
URL:https://www.dementiaresearcher.nihr.ac.uk/event/dementia-research-brain-health/
LOCATION:St Catherine’s College\, Manor Road\, Oxford\, Oxfordshire\, OX1 3UJ\, United Kingdom
CATEGORIES:Public Discussion
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2023/02/ALZHEIMERS-RESEARCH-UK-Logo.png
ORGANIZER;CN="Alzheimer's Research UK":MAILTO:infoline@alzheimersresearchuk.org
GEO:51.7571509;-1.2435143
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=St Catherine’s College Manor Road Oxford Oxfordshire OX1 3UJ United Kingdom;X-APPLE-RADIUS=500;X-TITLE=Manor Road:geo:-1.2435143,51.7571509
END:VEVENT
END:VCALENDAR